Determinants of societal and academic recognition: Evidence from randomised controlled trials

2021 ◽  
pp. 016555152110396
Author(s):  
Hajar Sotudeh ◽  
Adeleh Asadi ◽  
Zahra Yousefi

Given the increasing importance of recognition in academia and the vital role of randomised controlled trials (RCTs) in medical research and clinical decisions, this study verifies how RCTs’ academic and societal impacts are affected by visibility factors, subjects and methodological validity. This study concentrated on a sample of 446 RCTs indexed in Scopus and evaluated by Cochrane reviewers in terms of their methodological validity. The altmetrics, bibliometric and bibliographical information were extracted from Altmetric.com and Scopus, and the contributing countries’ development ranks were obtained from the United Nations Development report. The linear regression analyses revealed that citations and altmetrics depend on some subjects. They are also affected by publication year and journals’ previous reputation. Citations are also affected by keyword counts and reference counts. Keyword counts and contributing countries’ developmental rank also predict the tweet counts. While none of the methodological validity dimensions were found to predict citations, ‘Incomplete Outcome Data’ and ‘Random Sequence Generation’ significantly, though slightly, affect Mendeley Readership and tweets, respectively. By confirming the dependence of RCTs’ recognition on some methodological validity features and attention-inducing characteristics, the study provides further evidence on the interaction of quality and visibility dynamisms in the recognition network and the complementary role of societal mentions for academic citation.

2008 ◽  
Vol 36 (2) ◽  
pp. 152-161 ◽  
Author(s):  
R. P. Chalwin ◽  
J. L. Moran ◽  
P. L. Graham

The role of Extra corporeal membrane oxygenation (ECMO) has not been formally validated for patients with adult respiratory distress syndrome. In anticipation of publication of the conventional ventilation versus ECMO in severe adult respiratory failure (CESAR) trial, the role of ECMO in this setting was reviewed. An electronic search for studies reporting the use of ECMO for the treatment of adult respiratory distress syndrome revealed two randomised controlled trials and three non-controlled trials. Bayesian analysis on the two randomised controlled trials produced an odds ratio mortality of 1.28 (credible interval 0.24 to 6.55) demonstrating no significant harm or benefit. Pooling was not possible for the non-controlled studies because of differing admission status and ECMO selection criteria and an inability to control for these differences in the absence of individual patient data. A large number (n=35) of case series have been published with generally more positive results. We also present a comprehensive narrative commentary on the history, current practice and future for ECMO. ECMO, as rescue therapy for adult respiratory distress syndrome, appears to be an unvalidated rescue treatment option. Analysis and review of trial data does not support its application; however the body of reported cases suggests otherwise. Until the CESAR trial provides an authoritative answer ECMO will continue to be offered on a case by case basis.


2005 ◽  
Vol 5 (7) ◽  
pp. 431-439 ◽  
Author(s):  
Konstantinos Z Vardakas ◽  
George Samonis ◽  
Stavroula A Chrysanthopoulou ◽  
Ioannis A Bliziotis ◽  
Matthew E Falagas

2008 ◽  
Vol 44 (17) ◽  
pp. 2623-2626 ◽  
Author(s):  
A.G.K. McNair ◽  
C.T.P. Choh ◽  
C. Metcalfe ◽  
D. Littlejohns ◽  
C.P. Barham ◽  
...  

2002 ◽  
Vol 82 (2) ◽  
pp. 149-158 ◽  
Author(s):  
R Faris ◽  
M Flather ◽  
H Purcell ◽  
M Henein ◽  
P Poole-Wilson ◽  
...  

2019 ◽  
Vol 63 (7) ◽  
pp. 520 ◽  
Author(s):  
JeetinderK Makkar ◽  
NarinderP Singh ◽  
Vincent Wourms ◽  
Andrés Zorrilla-Vaca ◽  
RonaldB Cappellani ◽  
...  

BMJ Open ◽  
2019 ◽  
Vol 9 (4) ◽  
pp. e025145
Author(s):  
Bianca E Kavanagh ◽  
Sharon Lee Brennan-Olsen ◽  
Alyna Turner ◽  
Olivia M Dean ◽  
Michael Berk ◽  
...  

IntroductionRemission rates for mood disorders, including depressive and bipolar disorders, remain relatively low despite available treatments, and many patients fail to respond adequately to these interventions. Evidence suggests that personality disorder may play a role in poor outcomes. Although personality disorders are common in patients with mood disorders, it remains unknown whether personality disorder affects treatment outcomes in mood disorders. We aim to review currently available evidence regarding the role of personality disorder on pharmacological interventions in randomised controlled trials for adults with mood disorders.Methods and analysisA systematic search of Cochrane Central Register of Controlled Clinical Trials (CENTRAL) via cochranelibrary.com, PubMed via PubMed, EMBASE via embase.com, PsycINFO via Ebsco and CINAHL Complete via Ebsco databases will be conducted to identify randomised controlled trials that have investigated pharmacological interventions in participants aged 18 years or older for mood disorders (ie, depressive disorders and bipolar spectrum disorders) and have also included assessment of personality disorder. One reviewer will screen studies against the predetermined eligibility criteria, and a second reviewer will confirm eligible studies. Data will be extracted by two independent reviewers. Methodological quality and risk of bias will be assessed using the Cochrane Risk of Bias tool. A systematic review, and if sufficient evidence is identified, a meta-analysis will be completed. Meta-analysis will be conducted using the standardised mean difference approach and reported with 95% CIs. A random effects model will be employed and statistical heterogeneity will be evaluated using the I2 statistic. Prespecified subgroup analyses will be completed.Ethics and disseminationAs this systematic review will use published data, ethics permission will not be required. The outcomes of this systematic review will be published in a relevant scientific journal and presented at a research conference.Trial registration numberCRD42018089279.


Sign in / Sign up

Export Citation Format

Share Document